PGAM1 inhibition synergizes with anti-PD-1 immunotherapy significantly remodeling the tumor microenvironment and leading to an increase in antitumor immunocytes and a reduction in immunosuppressive cell infiltration (51). Here, PGAM1 is linked to neoplasm.